Incidence and predictors of first line antiretroviral regimen modification in western Kenya.

Limited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated...

Full description

Bibliographic Details
Main Authors: Seth Inzaule, Juliana Otieno, Joan Kalyango, Lillian Nafisa, Charles Kabugo, Josephine Nalusiba, Daniel Kwaro, Clement Zeh, Charles Karamagi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3973699?pdf=render
id doaj-37edc4fa28c742dbae2700fc0ad2ecbe
record_format Article
spelling doaj-37edc4fa28c742dbae2700fc0ad2ecbe2020-11-25T02:15:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9310610.1371/journal.pone.0093106Incidence and predictors of first line antiretroviral regimen modification in western Kenya.Seth InzauleJuliana OtienoJoan KalyangoLillian NafisaCharles KabugoJosephine NalusibaDaniel KwaroClement ZehCharles KaramagiLimited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated cART between January 2009 and January 2011 in western Kenya.cART modification was defined as either first time single drug substitution or switch. Incidence rates were determined by Poisson regression and risk factor analysis assessed using multivariate Cox regression modeling.Over a median follow-up period of 10.7 months, 178 (18.7%) patients modified regimens (incidence rate (IR); 18.6 per 100 person years [95% CI: 16.2-21.8]). Toxicity was the most common cited reason (66.3%). In adjusted multivariate Cox piecewise regression model, WHO disease stage III/IV (aHR; 1.82, 95%CI: 1.25-2.66), stavudine (d4T) use (aHR; 2.21 95%CI: 1.49-3.30) and increase in age (aHR; 1.02, 95%CI: 1.0-1.04) were associated with increased risk of treatment modification within the first year post-cART. Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively). Beyond one year of treatment, d4T use (aHR; 2.75, 95% CI: 1.25-6.05), baseline CD4 counts ≤350 cells/mm3 (aHR; 2.45, 95%CI: 1.14-5.26), increase in age (aHR; 1.05 95%CI: 1.02-1.07) and high baseline weight >60kg aHR; 2.69 95% CI: 1.58-4.59) were associated with risk of cART modification.Early treatment initiation at higher CD4 counts and avoiding d4T use may reduce treatment modification and subsequently improve sustainability of patients on the available limited options.http://europepmc.org/articles/PMC3973699?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Seth Inzaule
Juliana Otieno
Joan Kalyango
Lillian Nafisa
Charles Kabugo
Josephine Nalusiba
Daniel Kwaro
Clement Zeh
Charles Karamagi
spellingShingle Seth Inzaule
Juliana Otieno
Joan Kalyango
Lillian Nafisa
Charles Kabugo
Josephine Nalusiba
Daniel Kwaro
Clement Zeh
Charles Karamagi
Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
PLoS ONE
author_facet Seth Inzaule
Juliana Otieno
Joan Kalyango
Lillian Nafisa
Charles Kabugo
Josephine Nalusiba
Daniel Kwaro
Clement Zeh
Charles Karamagi
author_sort Seth Inzaule
title Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
title_short Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
title_full Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
title_fullStr Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
title_full_unstemmed Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
title_sort incidence and predictors of first line antiretroviral regimen modification in western kenya.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Limited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated cART between January 2009 and January 2011 in western Kenya.cART modification was defined as either first time single drug substitution or switch. Incidence rates were determined by Poisson regression and risk factor analysis assessed using multivariate Cox regression modeling.Over a median follow-up period of 10.7 months, 178 (18.7%) patients modified regimens (incidence rate (IR); 18.6 per 100 person years [95% CI: 16.2-21.8]). Toxicity was the most common cited reason (66.3%). In adjusted multivariate Cox piecewise regression model, WHO disease stage III/IV (aHR; 1.82, 95%CI: 1.25-2.66), stavudine (d4T) use (aHR; 2.21 95%CI: 1.49-3.30) and increase in age (aHR; 1.02, 95%CI: 1.0-1.04) were associated with increased risk of treatment modification within the first year post-cART. Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively). Beyond one year of treatment, d4T use (aHR; 2.75, 95% CI: 1.25-6.05), baseline CD4 counts ≤350 cells/mm3 (aHR; 2.45, 95%CI: 1.14-5.26), increase in age (aHR; 1.05 95%CI: 1.02-1.07) and high baseline weight >60kg aHR; 2.69 95% CI: 1.58-4.59) were associated with risk of cART modification.Early treatment initiation at higher CD4 counts and avoiding d4T use may reduce treatment modification and subsequently improve sustainability of patients on the available limited options.
url http://europepmc.org/articles/PMC3973699?pdf=render
work_keys_str_mv AT sethinzaule incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT julianaotieno incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT joankalyango incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT lilliannafisa incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT charleskabugo incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT josephinenalusiba incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT danielkwaro incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT clementzeh incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
AT charleskaramagi incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya
_version_ 1724896287557419008